Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2;5(10):5346-5355.
doi: 10.1021/acsomega.9b04381. eCollection 2020 Mar 17.

Low Toxicity, High Resolution, and Red Tissue Imaging in the Vivo of Yb/Tm/GZO@SiO2 Core-Shell Upconversion Nanoparticles

Yandong Bai  1 , Yuemei Li  2 , Rui Wang  2 , Yongmei Li  3
Affiliations

Low Toxicity, High Resolution, and Red Tissue Imaging in the Vivo of Yb/Tm/GZO@SiO2 Core-Shell Upconversion Nanoparticles

Yandong Bai et al. ACS Omega. .

Abstract

Lanthanide-doped upconversion nanoparticles (UCNPs) have attracted great attention in bioimaging applications. However, the stability and resolution of bioimaging based on UCNPs should be further improved. Herein, we synthesized SiO2-coated Ga(III)-doped ZnO (GZO) with lanthanide ion Yb(III) and Tm(III) (Yb/Tm/GZO@SiO2) UCNPs, which realized red fluorescence imaging in heart tissue. With increasing injection concentrations of Yb/Tm/GZO@SiO2 (1-10 mg/kg), the red fluorescence imaging intensity of heart tissue gradually increased. Moreover, the experimental results of toxicity in vitro and histological assessments of representative organs in vivo were studied, indicating that Yb/Tm/GZO@SiO2 UCNPs had low biological toxicity. These results proved that Yb/Tm/GZO@SiO2 can be used as a probe for fluorescence imaging in vivo.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Scheme 1
Scheme 1. Schematic Representation of the Imaging Mechanism of the Live Cell with Injection of UCNPs
Figure 1
Figure 1
(A) SEM and TEM characterization of Yb/Tm/GZO (Ga: 10 mol %, Yb: 7 mol %, Tm: 0.5 mol % mol %) UCNPs. (B) Synthesis process of the Yb/Tm/GZO@SiO2 core/shell structure. (C) TEM images of Yb/Tm/GZO@SiO2 with different contents of TEOS from 0.36 to 0.90 mL. (D) Size distribution of Yb/Tm/GZO@SiO2 with 0.60 mL of TEOS by gauss fitting.
Figure 2
Figure 2
(A) X-ray diffraction spectra of Yb/Tm/GZO and Yb/Ym/GZO@SiO2 nanoparticles. (B) FTIR spectra of Yb/Tm/GZO and Yb/Ym/GZO@SiO2 nanoparticles. (C) Ultraviolet–visible (UV–vis) absorption spectra of Yb/Tm/GZO and Yb/Tm/GZO@SiO2 nanoparticles. (D) Upconversion luminescence spectra of Yb/Tm/GZO@SiO2 with different TEOS contents. (E) Decay lifetime for the 650 nm band for Yb/Tm/GZO@SiO2 with different TEOS concentrations from 0 to 0.9 mL. (F) UCL intensities of Yb/Tm/GZO@SiO2 (TEOS: 0.6 mL) with different assembly times from 0 to 25 days at room temperature; the inset shows the digital photographs of Yb/Tm/GZO@SiO2 (TEOS: 0.6 mL) with different assembly times from 0 to 25 days.
Figure 3
Figure 3
(A) Scheme of the proposed nanostructure. (B) Corresponding log (UC intensity)–log (excitation power) curve of Yb/Tm/GZO@SiO2 nanoparticles. (C) Proposed energy transfer mechanism of Yb/Tm/GZO@SiO2 under 980 nm excitation.
Figure 4
Figure 4
(A) 7702 cell viability after incubating with different charged Yb/Tm/GZO@SiO2 concentrations ranging from 100 to 800 μg/mL for 24, 48, and 72 h. (B) HpG2 cell viability after incubating with different charged Yb/Tm/GZO@SiO2 concentrations ranging from 100 to 800 μg/mL for 24, 48, and 72 h.
Figure 5
Figure 5
Serum levels after tail vein injection with Yb/Tm/GZO@SiO2 with different concentrations (1–10 mg/kg) at 24 h and 7 days. (A) albumin (ALB); (B) alkaline phosphatase (ALP); (C) alanine transaminase (ALT); (D) aspartate aminotransferase (AST); (E) cholesterol (CHOL); (F) creatine kinase (CK); (G) total protein (TP); (H) creatinine (CRE); (I) uric acid (UA); (J) urea (UREA). Standard error of mean (SEM). Note: all data are presented as mean ± SEM (n = 8).
Figure 6
Figure 6
Confocal imaging (top) and bright-field (bottom) images of myocardial tissue following 24 h incubation with different Yb/Tm/GZO@SiO2 contents. (a, d) 1 mg/kg, (b, e) 6 mg/kg, and (c, f) 10 mg/kg. The excitation at 980 nm was provided from a pulsed laser, and the red emission was captured by channel set at 640–660 nm (120 × 10 oil lens, scale bar = 50 μm).
See this image and copyright information in PMC

References

    1. Nyk M.; Kumar R.; Ohulchanskyy T. Y.; Bergey E. J.; Prasad P. N. High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008, 8, 3834–3838. 10.1021/nl802223f. - DOI - PMC - PubMed
    1. Zhou J.; Sun Y.; Du X.; Xiong L.; Hu H.; Li F. Dual-modality in vivo, imaging using rare-earth nanocrystals with near-infrared to near-infrared (NIR-to-NIR) upconversion luminescence and magnetic resonance properties. Biomaterials 2010, 31, 3287–3295. 10.1016/j.biomaterials.2010.01.040. - DOI - PubMed
    1. Haun J. B.; Devaraj N. K.; Marinelli B. S.; Lee H.; Weissleder R. Probing Intracellular Biomarkers and Mediators of Cell Activation Using Nanosensors and Bioorthogonal Chemistry. ACS Nano 2011, 5, 3204–3213. 10.1021/nn200333m. - DOI - PMC - PubMed
    1. Sharma P.; Brown S.; Walter G.; Santra S.; Moudgil B. Nanoparticles for bioimaging. Adv. Colloid Interface Sci. 2006, 123–126, 471–485. 10.1016/j.cis.2006.05.026. - DOI - PubMed
    1. Pan D.; Caruthers S. D.; Chen J.; Winter P. M.; SenPan A.; Schmieder A. H.; Wickline S. A.; Lanza G. M. Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med. Chem. 2010, 2, 471–490. 10.4155/fmc.10.5. - DOI - PMC - PubMed